Roche’s Genentech inked a discovery collaboration with Earendil Labs for bispecific antibodies in oncology, paying $55 million upfront and setting total potential value above $1.5 billion based on milestones. The agreement centers on using Earendil’s approach to generate and advance multiple bispecific candidates. For Genentech, the pact extends a growing emphasis on bispecific formats aimed at improving tumor targeting and therapeutic depth in hard-to-treat cancers. For Earendil, it provides non-dilutive validation of its discovery platform by a major incumbent with deep development and regulatory infrastructure. The timing matters for the sector because bispecific competition is intensifying, with discovery-stage deals increasingly being used to secure differentiated pipelines early—before clinical differentiation is visible.